Company Overview
About Persephone Biosciences
Persephone Biosciences is a biotechnology company founded in 2017 by Stephanie Culler and Chris Calvert and based in San Diego, California. The company focuses on decoding the human gut microbiome to develop diagnostics and therapeutics in oncology and neonatal health. Its core thesis is that the composition of a patient's microbiome significantly affects how they respond to cancer immunotherapies such as checkpoint inhibitors — a hypothesis supported by a growing body of peer-reviewed clinical research. Persephone's diagnostic platform aims to predict immunotherapy response from a patient's microbiome signature prior to treatment initiation.
Business Model & Competitive Advantage
The company's therapeutic pipeline leverages synthetic biology to engineer microbial communities and metabolites that can modulate immune response in cancer patients. In parallel, Persephone has pursued microbiome-based interventions for infant health, including programs targeting necrotizing enterocolitis (NEC), a severe gastrointestinal condition in preterm infants. The company received funding from the Biomedical Advanced Research and Development Authority (BARDA), a US government agency, for its microbiome diagnostics work — providing both capital validation and a regulatory pathway anchor.
Competitive Landscape 2025–2026
Persephone Biosciences competes in the emerging microbiome medicine space alongside companies like Seres Therapeutics and Vedanta Biosciences but occupies a distinct niche through its dual focus on oncology companion diagnostics and infant health. The company has pursued collaborations with major cancer centers to validate its predictive platform in clinical settings. As microbiome science matures and companion diagnostics gain regulatory traction, Persephone's combined diagnostics-plus-therapeutics strategy could prove to be a meaningful differentiator in the oncology precision medicine market.
Key Differentiators
Emerging Innovator
Persephone Biosciences is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Similar Brands
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Compare Persephone Biosciences with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Persephone Biosciences? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Persephone Biosciences Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Persephone Biosciences vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →